Innovative BBB Research HUREL, now part of Visikol, specializes in developing blood-brain barrier (BBB) assays and models, showcasing a strong focus on BBB permeability and transport mechanisms. This presents opportunities to offer advanced drug delivery solutions and analytical services tailored to neuropharmacology and CNS-focused clients.

Expanded Imaging Capabilities With recent launches of multiplex tissue imaging and Imaging Mass Cytometry services, Visikol demonstrates cutting-edge imaging technology expertise. This can be leveraged to attract customers seeking high-throughput, high-precision tissue analysis and biomarker discovery solutions.

Research in Tissue Models The company has developed a suite of human and animal organ tissue slice models, including kidney and liver, enabling more accurate in vitro studies. Targeting pharmaceutical companies and academic research institutions needing sophisticated tissue-based assays presents a clear sales opportunity.

Recent R&D Developments Ongoing investments in BBB assays and tissue models, along with partnerships to enhance imaging capabilities, indicate a focus on innovative, high-value research tools. Promoting these advanced R&D services to biotech and pharma firms working on CNS, liver, or kidney therapies could open new revenue streams.

Growing Revenue Potential With a revenue range of 10 to 25 million dollars and recent technological expansions, Visikol is positioned for growth in the biotech research sector. Engaging companies looking for comprehensive in vitro and imaging solutions can capitalize on this growth potential.